Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer ResearchĀ·2026
Same author

A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.

The ProstateĀ·2026
Same author

Dose response OECD 216 studies for agrochemicals.

Integrated environmental assessment and managementĀ·2026
Same author

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

The Journal of clinical investigationĀ·2026
Same author

Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST).

BJU internationalĀ·2026
Same author

Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.

The ProstateĀ·2026
Same journal

Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size-dependent survival in pT3N0M0 clear cell renal cell carcinoma.

Urologic oncologyĀ·2026
Same journal

Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4-5 lesions.

Urologic oncologyĀ·2026
Same journal

Testis-sparing surgery for small testicular masses: Functional and oncological outcomes.

Urologic oncologyĀ·2026
Same journal

Subcapsular versus total orchiectomy in advanced prostate cancer: A systematic review and meta-analysis of clinical and patient-reported outcomes.

Urologic oncologyĀ·2026
Same journal

Featured SUO Fellow: Soum Lokeshwar, MD MBA.

Urologic oncologyĀ·2026
Same journal

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Urologic oncologyĀ·2026
See all related articles

Related Experiment Video

Updated: Mar 31, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012.

Michelle D Nezolosky1, Kathryn T Dinh2, Vinayak Muralidhar2

  • 1Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women׳s Hospital, Boston, MA.

Urologic Oncology
|October 19, 2015
PubMed
Summary
This summary is machine-generated.

Radical prostatectomy (RP) use for clinical T3 prostate cancer significantly increased from 1998 to 2012, surpassing radiation therapy. Treatment patterns shifted, with fewer patients receiving no curative therapy.

Keywords:
Clinical T3 diseaseProstate cancerProstatectomyRadiation therapyTreatment patterns

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 31, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Area of Science:

  • Urology
  • Oncology
  • Cancer Research

Background:

  • Clinical T3 prostate cancer (PCa) requires careful treatment selection.
  • Understanding treatment trends is crucial for optimizing patient outcomes.

Observation:

  • A significant shift in treatment patterns for clinical T3 PCa occurred between 1998 and 2012.
  • Radical prostatectomy (RP) rates increased substantially, while radiation therapy rates decreased.
  • No curative therapy also saw a decline, indicating a move towards active treatment.

Findings:

  • RP use rose from 12.5% to 44.4%, exceeding radiation therapy (55.8% to 38.4%) by 2012.
  • Gleason score, PSA levels, and patient age influenced the likelihood of receiving RP versus radiation.
  • Treatment trends were consistent across clinical T3a and T3b stages.

Implications:

  • The findings highlight a major evolution in the management of advanced prostate cancer.
  • This shift suggests a growing preference for surgical intervention in specific patient groups.
  • Further research should explore the long-term oncological outcomes associated with these changing treatment paradigms.